Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 48%
Buy 52%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is a global leader in the medical device industry and has a strong portfolio of products in various segments. With reported revenue and earnings growth, the company is poised for future success through product launches and investments. However, competitors, supply chain disruptions, and geopolitical concerns could present challenges to their growth plans. Overall, Boston Scientific is well-positioned but faces potential risks in the competitive market.

Bears say

Boston Scientific is facing several headwinds that may negatively impact their revenue growth and earnings per share (EPS) forecast, leading me to have a negative outlook on the company's stock. Management lowered their 2026 revenue growth guidance from 10.5-11.5% to 7.0-8.5% and organic revenue growth guidance from 10.0-11.0% to 6.5-8.0%, while also lowering EPS guidance, signaling potential challenges and slower growth ahead. Additionally, the company is facing competitive pressures in certain segments, such as Urology and CRM, and has experienced disruptions in supply chain and business operations. These factors may limit the company's ability to achieve its long-term revenue and earnings targets. Furthermore, the recent announcement of a $2 billion buyback may not be enough to offset these headwinds and drive significant shareholder returns in the short term.

Boston Scientific (BSX) has been analyzed by 21 analysts, with a consensus rating of Buy. 48% of analysts recommend a Strong Buy, 52% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 21 analysts, Boston Scientific (BSX) has a Buy consensus rating as of May 6, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $91.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $91.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.